Bayer Corporation

Mayo Foundation for Medical Education and Research

Bayer Healthcare LLC

Chiron Diagnostics Corporation

Marcia E Lewis

Jon H Astle

Theodore J Catino

Christopher C Burgess

Poornima Dwivedi

Gary A Molino

John E Monahan

Robert Schlegel

Donna M Ford

Wilson O Endege

Eddie Carroll, Iii

Kathleen E Steinmann

Stephen N Thibodeau

Susan H Myerow

Arunthathi Thiagalingam

Lawrence J Burgart

Lisa Allyn Boardman

Gurpreet S Sandhu

Bruce C Kline

Steven E Bushnell

Glenn D Roberts

Adnan Derti

Leslie Stockman

This invention relates to novel human genes, to proteins expressed by the genes, and to variants of the proteins. The invention also relates to diagnostic assays and therapeutic agents related to the genes and proteins, including probes, antisense constructs, and antibodies. The subject nucleic acids have been found to be differentially regulated in tumor cells, particularly in colon cancer tissue.

Method for detecting a differentially expressed sequence

Human genes and gene expression products: II

Human genes and expression products: II

This invention relates to novel human genes, to proteins expressed by the genes, and to variants of the proteins. The invention also relates to diagnostic assays and therapeutic agents related to the genes and proteins, including probes, antisense constructs. and antibodies. The subject nucleic acids have been found to be differentially regulated in tumor cells, particularly colon cancer cell lines and/or tissue.

Human genes and gene expression products

The detection of the IS6110 insertion element in a clinical specimen is a rapid way of diagnosing infection by Mycobacterium tuberculosis. A reliable diagnostic test for tuberculosis based on the IS6110 DNA is described in this disclosure. A 'Universal' specimen preparation protocol that eliminates live organisms and purifies nucleic acids from all types of clinical specimens is described. Two nucleic acid primers designed to amplify IS6110 DNA with high specificity in a polymerase chain reaction are also described. The amplified IS6110 DNA is identified by a restriction endonuclease and electrophoresis based assay. The identification process also renders the DNA unamplifiable in a subsequent PCR, thereby reducing the possibility of contaminating other specimens. Time, labor and cost is minimized, while user safety and test reliability are maximized. The complete DNA extraction, amplification and analysis is accomplished with ease within an 8 hour period, with a sensitivity of 92% and a specificity approaching 100%. Testing of serially obtained samples from the same patient increases the overall rate of detection to 100%.

IS6110 based molecular detection of mycobacterium tuberculosis

Growing community of inventors

Cohasset, MA, United States of America

Marcia E Lewis